» Articles » PMID: 16536756

Multiple Primary Malignancies in Patients with Renal Cell Carcinoma: a National Population-based Cohort Study

Overview
Journal BJU Int
Specialty Urology
Date 2006 Mar 16
PMID 16536756
Citations 64
Authors
Affiliations
Soon will be listed here.
Abstract

Objective: To determine the possibly greater occurrence of multiple malignancies in patients with renal cell carcinoma (RCC).

Patients And Methods: In the 7-year period 1987-93, all 1425 patients aged 15-70 years with registered histopathologically verified RCC in Norway were included in the study. All clinical and histopathology reports were checked manually, to verify the registered diagnosis and to ensure that no tumour was a metastasis from another. After this process, 257 patients (287 tumours other than RCC) with multiple primary malignancies were identified. The primary tumours other than RCC were classified as antecedent, synchronous and subsequent. For the subsequently occurring tumours, the expected number of different tumour types was calculated according to age group, gender and observation time.

Results: Of the 1425 patients, 228 (16%) had one, 23 (1.6%) had two, three (0.2%) had three and one (0.07%) had four other primary malignancies. In all, 100 (34.8%) of the other tumours were diagnosed as antecedent, 53 (18.7%) as synchronous and 134 (46.7%) as subsequent to the RCC. Cancer in the prostate, bladder, lung, breast, colon and rectal cancer, malignant melanomas (MM) and non-Hodgkin's lymphomas (NHL) were the most common other malignancies. The observed overall number of subsequent other malignant tumours was 22% higher than the expected number. The observed number of subsequent tumours was significantly higher for bladder cancer, NHL and MM. The estimated 15-year cumulative risk for patients with RCC and no previous or synchronous other malignancy for developing a later second cancer was 26.6% in men, and 15.5% in women (statistically significant, P = 0.04). Patients with antecedent or synchronous other cancer had significantly poorer overall survival than those without.

Conclusions: Patients with RCC seem to have a significantly higher risk of developing other subsequent primary malignancies. This should be considered during the follow-up of patients with RCC.

Citing Articles

A rare metachronous primary clear cell renal cell carcinoma and pancreatic ductal adenocarcinoma: case report and literature review.

Zhu Y, Zhou C, Kong F, Liu X, Wang X, Chen J Am J Transl Res. 2024; 16(10):5743-5748.

PMID: 39544741 PMC: 11558432. DOI: 10.62347/DVRS3715.


Case report: Synchronous prostate cancer and renal cell carcinoma with prostate cancer-origin metastases to adrenal and renal hilar lymph nodes.

Zhang Y, Chen J, Xu L, Hu X, Zeng H, Liu Z Front Oncol. 2024; 14:1412067.

PMID: 39435284 PMC: 11491287. DOI: 10.3389/fonc.2024.1412067.


A nomogram for overall survival of second primary cancers following upper-tract urothelial carcinoma: a SEER population-based study.

Zhang X, Chen W, Li C, Wan X, Xu P, Zhang T Transl Cancer Res. 2024; 13(8):4131-4145.

PMID: 39262482 PMC: 11385250. DOI: 10.21037/tcr-24-515.


AP-2α gene deregulation is associated with renal cell carcinoma patient survival.

Lin P, Hsieh C, Yu K, Shao I, Chuang C, Hsu T BMC Cancer. 2024; 24(1):966.

PMID: 39112969 PMC: 11304775. DOI: 10.1186/s12885-024-12526-w.


Renal cell carcinoma and risk of second primary cancer: A Danish nationwide cohort study.

Bengtsen M, Farkas D, Sorensen H, Norgaard M Cancer Med. 2024; 13(11):e7237.

PMID: 38872360 PMC: 11176587. DOI: 10.1002/cam4.7237.